EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

ESMO Gastrointestinal Oncology

ISSN 2949-8198 · Elsevier BV

Latest articles

  1. Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma—the IKF-t90/AIO/ZANGEA trial with translational analysis

    J. Gorgulho, J. Tintelnot, E. Gökkurt, S.E. Al-Batran, S. Lorenzen, T. Götze, K. Heinrich, A. Kurreck, M. Moehler, D. Arnold, T. Dechow, T. Ettrich, N. Homann, U. Lindig, C. Müller, V. Rempel, A. Schlenska-Lange, H. Schmalenberg, P. Thuss-Patience, K. Wegehenkel, A. Stein

    Published: 2026-12DOI: 10.1016/j.esmogo.2026.100444

  2. Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain

    N. Martínez-Lago, M. Reboredo López, M.C. Riesco Martínez, S. López Peraita, B. González Gómez, C. Antonilli Pérez, I. Ghanem, M. Pérez Martelo, A. López Alfonso, A. Fernández Montes, S. Agraso Busto, A.M. Jiménez Gordo, M. Melian Sosa, E. Gallardo Martín, L. Cabezón-Gutiérrez, A. Cousillas Castiñeiras, M. LLanos Muñoz, M.P. Ochoa Rivas, D. Gutiérrez Abad, J. de la Cámara Gómez, B. De Frutos González, A.M. López Muñoz, R. Ferreiro Monteagudo

    Published: 2026-09DOI: 10.1016/j.esmogo.2026.100404

  3. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study

    G. Trovato, M. Carullo, A. Nicastro, C. Spoto, E. Perissinotto, G. Giordano, E. Di Giacomo, M.A. Calegari, V. Pasquinucci, T. Troiani, S. Tamberi, M. Schirripa, M. Scartozzi, F. Morano, G. Arrivi, C. Morelli, M. Basso, M. Landi, E. Martinelli, F. Zoratto, F. Bergamo, M. Landriscina, J. Lucchetti, C. Cremolini, G. Tortora, L. Salvatore

    Published: 2026-06DOI: 10.1016/j.esmogo.2026.100317

  4. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study

    H. Vandeputte, A. Casadei-Gardini, F. Peeters, M. Rimini, F. Nichetti, A. Saborowski, L. Antonuzzo, L. Passeri, T. Satake, C. Vivaldi, T. Pressiani, J. Lucchetti, J.W. Kim, O. Abidoye, S. Corallo, I.G. Rapposelli, S. Tamberi, F. Finkelmeier, G. Giordano, C. Pircher, H.J. Chon, C. Braconi, A. Qaisar, C. Pirrone, F. Castet, E. Tamburini, C. Yoo, A. Parisi, A. Lancianese, A. Diana, M. Scartozzi, G.W. Prager, A. Avallone, M. Schirripa, I.H. Kim, L. Perkhofer, E. Oneda, M. Verrico, N. Couto, J. Adeva

    Published: 2026-06DOI: 10.1016/j.esmogo.2026.100335

Volumes

2026 · 1292025 · 1402024 · 662023 · 17

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.